Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
Jun 23, 2025DOI: 10.1161/circulationaha.125.074037Journal ArticleAHA
Written by: Samer Al SaidSiddharth M PatelRobert P GiuglianoDavid A MorrowErica L GoodrichSabina A MurphyBruce HugSanobar ParkarShih-Ann ChenShaun G GoodmanBoyoung JoungRobert G KissWojciech WojakowskiJeffrey I WeitzDan BloomfieldMarc S SabatineChristian T Ruff
Anticoagulation is the mainstay of therapy to reduce thromboembolic risk in patients with atrial fibrillation (AF).1,2 Estimates suggest that 40% of individuals with AF also have atherosclerotic cardiovascular disease (ASCVD), with approximately 10% of patients with AF ultimately requiring antiplatelet therapy due to a recent percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS).1–3 However, the use of concomitant antiplatelet therapy with currently available oral anticoagulants (OACs), such as direct oral anticoagulants (DOACs) or warfarin, substantially increases the risk of bleeding.3–5Emerging factor XI (FXI) pathway inhibitors have reduced bleeding compared with DOACs.6,7 Accordingly, these therapies may be particularly attractive choices in minimizing bleeding in patients who require combination antithrombotic therapy, a population that has traditionally been at high risk for bleeding.7–12Abelacimab is a fully human monoclonal antibody that binds to the catalytic domain of the inactive form of FXI and prevents the generation of the activated form (FXIa).13 The AZALEA-TIMI 71 trial examined the relative safety of abelacimab compared with rivaroxaban in 1,287 patients with AF at moderate-to-high risk for stroke, with a median follow-up of 2.1 years.14 Randomization was stratified by the planned use of concomitant antiplatelet therapy. Leveraging the AZALEA-TIMI 71 dataset, we sought to characterize the treatment effect of abelacimab relative to rivaroxaban in the context of concomitant antiplatelet therapy.
METHODS
The study design and primary results, including inclusion and exclusion criteria, were previously published.14 Briefly, from March through December 2021 AZALEA-TIMI 71 enrolled patients ≥55 years of age with a CHA2DS2-VASc score ≥4 (or ≥3 if planned concomitant use of antiplatelet therapy or a creatinine clearance ≤50 ml/min). Eligible patients were randomly allocated 1:1:1 to monthly subcutaneous injections of abelacimab (150 mg or 90 mg) or rivaroxaban 20 mg by mouth daily (dose reduced to 15 mg in patients with creatinine clearance ≤ 50 mL/min), with randomization stratified by the planned continuation of concomitant antiplatelet therapy at the time of enrollment. The trial was double-blinded with respect to the two abelacimab doses but open-label between abelacimab and rivaroxaban. We encourage parties interested in data sharing to contact the corresponding author. The relevant ethics committees at the participating sites approved the trial protocol, and all participants provided written informed consent. This report adheres to the CONSORT reporting guidelines for randomized clinical trials (Supplemental Table 1).
The primary outcome for this analysis was major or clinically relevant non-major (CRNM) bleeding, as defined by the International Society on Thrombosis and Haemostasis.15 Other outcomes included major bleeding, a broader bleeding composite of major, CRNM, or minor bleeding, gastrointestinal major bleeding, gastrointestinal bleeding, stroke or systemic embolic event (SEE), and the net clinical outcome (NCO) composite of ischemic stroke/SEE, major or CRNM bleeding, or all-cause mortality. All outcomes except minor bleeding were adjudicated by an independent clinical events committee blinded to treatment assignment.
Baseline characteristics were examined by planned concomitant antiplatelet therapy and further examined by treatment allocation. The Wilcoxon rank sum test was employed for continuous variables, while the chi-squared test was used for categorical variables. All outcomes were examined using Cox proportional hazards adjusted for age, sex, and body mass index, with an interaction term for randomized treatment and antiplatelet therapy use. The proportional-hazards assumption was assessed and confirmed graphically and numerically using cumulative sums of martingale-based residuals 16. The on-treatment approach was used for all outcomes, which included patients within 60 days of the last dose of the study drug. All rates are reported as incidence rates per 100 person-years (PY). All p-values were 2-sided, with those <0.05 considered statistically significant. Statistical computations were performed with SAS v9.4 (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics stratified by concomitant antiplatelet therapy use are shown in Table 1. Of the 1,287 patients, 318 (24.7%) were treated with antiplatelet therapy at baseline with planned continuation (15.5% on aspirin only, 7.5% on P2Y12 inhibitor only, and 1.6% on dual antiplatelet therapy [DAPT]). Patients treated with antiplatelet therapy were younger (median age 72.0 vs. 75.0 years), more likely to be male (69.5% vs. 51.0%) and had a greater prevalence of ASCVD at baseline (coronary artery disease: 74.2% vs. 39.8%; prior myocardial infarction vs. 15.7%; and peripheral artery disease vs. 11.1%) compared with those not on antiplatelet therapy (p < 0.05 for each). Overall, 92% of patients were anticoagulation experienced (defined as receiving an oral anticoagulant for at least 60 days before enrollment), 90% in those taking concomitant antiplatelet therapy and 97% in those without. There were no clinically important differences among patients randomized to abelacimab vs. rivaroxaban when stratified by concomitant antiplatelet therapy use (Supplemental Tables 2 and 3). Concomitant antiplatelet therapy use remained stable in the abelacimab arms, while it decreased in the rivaroxaban arm over the study period (Supplemental Table 4).
The incidence of major or CRNM bleeding in the rivaroxaban arm was 10.6% per 100 PY in those receiving concomitant antiplatelet therapy versus 7.7% per 100 PY in those without. In contrast, in the abelacimab arms, the rates were 2.5% and 3.5% per 100 PY for the 90 mg and 150 doses, in those with concomitant antiplatelet therapy versus 2.7% and 3.1% per 100 PY, respectively, in those without (Supplemental Table 5). Each abelacimab dose significantly reduced major or CRNM bleeding compared with rivaroxaban, with a consistent relative reduction in the risk of major or CRNM bleeding in those with concomitant antiplatelet therapy (adjusted hazard ratio [aHR] 0.26 [95% CI 0.10–0.70] and aHR 0.30 [95% CI 0.12–0.74] for abelacimab 90 and 150 mg vs. rivaroxaban) compared with those without (aHR 0.34 [95% CI 0.19–0.60] and aHR 0.40 [95% CI 0.23–0.68]) (p-interactions 0.56 and 0.60, respectively). The absolute risk reduction tended to be greater in patients receiving concomitant antiplatelet therapy (−8.2% [95% CI: −10.7%, −5.7%] and 7.1% [−9.7%, −4.5%] per 100 PY for abelacimab 90 and 150 mg vs. rivaroxaban compared to those without (−5.0% −6.3%, −3,7%] and −4.6% −5.9%, −3.3%] per 100 PY, respectively) (Figure 1 and Supplemental Figure 1).
Both abelacimab doses reduced major bleeding relative to rivaroxaban, with a consistent treatment effect in those with concomitant antiplatelet therapy (aHR 0.21 [0.05–0.99] and aHR 0.36 [0.10–1.32] for abelacimab 90 and 150 mg vs. rivaroxaban) compared with those without (aHR 0.27 [0.11–0.67] and aHR 0.31 [0.13–0.73]) (p-interaction = 0.86 and 0.87 for abelacimab 90 and 150 mg vs. rivaroxaban, respectively; Figure 2). Similarly, both abelacimab doses significantly reduced the composite of major, CRNM, or minor bleeding relative to rivaroxaban with a consistent treatment effect in those with concomitant antiplatelet therapy (aHR 0.71 [0.51–0.98] and aHR 0.58 [0.32–1.06] for abelacimab 90 and 150 mg vs. rivaroxaban) compared with those without (aHR 0.50 [0.34–0.72] and aHR 0.36 [0.18–0.72]) (p-interaction = 0.42 and 0.57 for abelacimab 90 and 150 mg vs. rivaroxaban, respectively; (Supplemental Figure 2). Among those treated with concomitant antiplatelet therapy, there were no gastrointestinal bleeds in either abelacimab arm. In contrast, the rivaroxaban arm had an incidence rate of 2.4% per 100 PY for major gastrointestinal bleeding and 3.5% per 100 PY for any GI bleeding (Supplemental Table 5).
A total of 28 stroke/SEE events occurred during trial follow-up, with no significant differences comparing either abelacimab dose to rivaroxaban when stratified by concomitant antiplatelet therapy (p-interaction 0.46 and 0.88; Supplemental Tables 6). In the rivaroxaban arm, the incidence rate of the NCO was 14.0% per 100 PY in those with concomitant antiplatelet therapy vs. 11.1% per 100 PY in those without; both abelacimab doses significantly reduced the NCO irrespective of antiplatelet therapy (p-interaction = 0.62 and 0.88; Supplemental Table 6).
DISCUSSION
In this analysis of patients with AF enrolled in the AZALEA-TIMI 71 trial, we observed consistent robust relative reductions in the risk of bleeding with the novel FXI inhibitor, abelacimab, when compared with rivaroxaban, irrespective of concomitant antiplatelet therapy. Moreover, owing to the higher bleeding rates observed in the rivaroxaban arm among those continuing antiplatelet therapy, abelacimab tended to provide a greater absolute risk reduction in this subset – a finding of clinical relevance given the synergistic increase in bleeding risk that has traditionally been observed across prior anticoagulant classes in combination with antiplatelet therapy.17–19 Collectively, these results reaffirm the promise of FXI pathway inhibition as a potentially safer platform for anticoagulation and indicate that these emerging therapies may be especially beneficial in patients who require concomitant antiplatelet therapy. This frequently encountered patient subgroup has typically posed challenges for antithrombotic management owing to the higher prevalence of both ischemic and bleeding risk factors.1–3
Several pivotal trials have examined the safety and efficacy of different doses of DOACs or warfarin coupled with various combinations of antiplatelet regimens (aspirin monotherapy, lower vs. higher potency P2Y12 inhibitors, or DAPT) among patients with AF undergoing PCI. In general, the results have suggested that dual therapy with a DOAC and a P2Y12 inhibitor (mostly clopidogrel) is safer with respect to major bleeding compared with triple antithrombotic therapy.4,20–26 Notably, however, these trials have not been adequately powered to detect differences in ischemic events. In that context, subsequent meta-analyses have suggested a potential trade-off, with a signal for an increased risk of stent thrombosis with a strategy of dual therapy (i.e., antiplatelet monotherapy plus DOAC), particularly in those undergoing PCI for ACS.24,25 While the combination of OAC and antiplatelet therapy has also been evaluated in populations solely with stable ASCVD or with ACS without an alternative indication for anticoagulation,17–19,27–32 such regimens are not routinely recommended in clinical practice owing to the prohibitive risk for bleeding. However, regimens consisting of very low dose DOAC have shown promise.28,29,32
In this study, contrary to what has been observed with prior anticoagulant classes, we did not observe a higher rate of bleeding in patients taking antiplatelet therapy on a background of FXI inhibition.28,29,32 Both doses of abelacimab had an absolute rate of major bleeding that was < 2% per 100 PY and consistently reduced bleeding compared with rivaroxaban regardless of antiplatelet therapy use, with a greater potential for absolute risk reduction of bleeding among those requiring concomitant antiplatelet therapy. Notably, gastrointestinal bleeding, which accounts for the majority of major anticoagulant-related bleeding and is often precipitated by the use of concomitant antiplatelet therapies,33 was absent in both abelacimab arms among the subgroup treated with antiplatelet therapy. Collectively, these findings suggest that FXI pathway inhibition may offer a safer anticoagulation platform for combination with antiplatelet therapy by mitigating the bleeding risks that have traditionally been associated with combination antithrombotic therapy. Moreover, while AZALEA-TIMI 71 was not designed to examine efficacy, if such FXI inhibitor therapies are demonstrated to be effective for reduction of ischemic events across ongoing larger phase 3 studies, coupling FXI pathway inhibition with potent antiplatelet therapy may represent a paradigm shift in conventional approaches to antithrombotic strategy, yielding perhaps an optimal balance by reducing bleeding risk yet maximizing efficacy for reduction of ischemic events of both atherosclerotic or cardioembolic etiologies. Our findings corroborate the results from other phase II FXI inhibitor trials in secondary non-cardioembolic ischemic stroke and post-ACS with more limited follow-up, where no clear increases in bleeding were seen with the addition of FXI inhibitor therapy compared to placebo among patients treated with background antiplatelet therapy.9–11 Notably, however, the number of bleeding events and total follow-up across these phase II studies of oral small molecule FXI inhibitors was limited. Additionally, none of these prior studies have compared the relative safety of combination antithrombotic therapy with factor XI inhibition relative to DOAC. Thus, our study builds upon these prior findings by extending these results to a contemporary patient population with AF, and further contextualizing the safety profile of combination antithrombotic therapy with factor XI inhibition compared with rivaroxaban.
AZALEA-TIMI 71 was not designed to assess efficacy endpoints; larger ongoing Phase III trials will be important for providing insights regarding the efficacy of abelacimab and other FXI inhibitors in reducing ischemic events, including when paired with antiplatelet therapy. Antiplatelet therapy used in our study primarily consisted of single antiplatelet therapy with aspirin; thus, we are unable to meaningfully examine the heterogeneity of treatment effect in patients treated with DAPT or only P2Y12 inhibition. Given that bleeding profiles likely vary across DOACs, the treatment effect of abelacimab vs. other DOACs by concomitant antiplatelet therapy may differ. Additionally, most patients we enrolled were White, so the generalizability of our findings to other racial groups may be limited.
FXI pathway inhibition with abelacimab results in significant reductions in bleeding compared with rivaroxaban, regardless of concomitant antiplatelet therapy use. These data support the notion that FXI pathway inhibition may prove to be particularly attractive in patients who require concomitant antiplatelet therapy, as these patients may derive greater absolute reductions in the rate of bleeding from these emerging therapies.
CR
Dr. Christian Ruff
Cardiology · General Non-Invasive CardiologyMass General Brighamchristianruff